Flu Vaccine Potency Remains Top Of Mind As US Panel Prepares To Pick Next Season's Strains
FDA advisory committee will vote on WHO's flu strain recommendations as agency hunts for root causes of low effectiveness of current season’s vaccine.
You may also be interested in...
Rather than holding half of all vaccines produced to ensure administration of the second dose, only a portion would be held to cover for manufacturing or other problems.
Developing a universal flu vaccine will be iterative process, National Institute of Allergy and Infectious Diseases Anthony Fauci says.
US health authorities, manufacturers investigating why egg-based product appears to have lower effect in adults compared to cell-based flu vaccine.